Comparison of Level of Pentraxin-3 in Gingival Crevicular Fluid with Chronic Periodontitis in Well Controlled and Uncontrolled Diabetes Mellitus Patients
DOI:
https://doi.org/10.70284/njirm.v9i2.2310Keywords:
chronic periodontitis, Diabetes mellitus, gingival crevicular fluid, One Way AnovaAbstract
Background and Aim: Periodontal diseases are characterized by a complex set of biologic interaction between a microbial ecosystem and the host's immune and inflammatory machinery, such interaction play a role in the development of periodontal disease via the release of inflammatory mediators. The usefulness of such inflammatory mediators as biomarkers for Chronic periodontitis in Diabetes Mellitus patients is unknown. In this study, we tested whether gingival crevicular fluid concentration of human Pentraxin – 3; a local inflammatory marker, would be a useful biomarker for detecting Chronic Periodontitis. Methods: 45 patients with chronic periodontitis were divided into 3 groups based on presence / absence of Diabetes mellitus and whether it is well controlled or not. Clinical parameters were recorded. The clinical and radiographic examinations, group allocations, and sampling site selection for all patients were performed. The samples were collected on the subsequent day using microcapillary pipettes. Collected samples were assayed using Enzymes linked immuonosorbent assay. Results: Statistical analysis was done using One Way Anova test, to compare between 3 groups. Independent sample t-test was done for 2 groups comparison. Statistically significant results were found between group A and group C for Russell's periodontal index. Statistically significant results were not found for Pentraxin-3 levels between groups. Conclusion: By this study we can conclude that Pentraxin – 3 in gingival crevicular fluid increases with increase in inflammation irrespective of the presence or absence of the systemic diseases.
References
2. Pradeep AR, Kathariya R, RaghavendraN M, and Sharma A. Levels of Pentraxin-3 in Gingival Crevicular Fluid and Plasma in Periodontal Health and Disease. J Periodontol 2011;82:734-741.
3. Caffesse RG, Nasjleti CE. Enzymatic penetration through intact sulcular epithelium. J Periodontol 1976;47:391-397.
4. Saglie R, Newman MG, Carranza FA Jr., Pattison GL. Bacterial invasion of gingiva in advanced periodontitis in humans. J Periodontol 1982;53:217-222.
5. Schwartz J, Stinson FL, Parker RB. The passage of tritiated bacterial endotoxin across intact gingival crevicular epithelium. J Periodontol 1972;43:270-276.
6. Tuter G, Kurtis B, Serdar M. Evaluation of gingival crevicular fluid and serum levels of high-sensitivity C-reactive protein in chronic periodontitis patients with or without coronary artery disease. J Periodontol 2007;78:2319-2324.
7. Fitzsimmons TR, Sanders AE, Bartold PM, Slade GD. Local and systemic biomarkers in gingival crevicular fluid increase odds of periodontitis. J Clin Periodontol 2010;37:30- 36.
8. Inoue K, Kodama T, Daida H. Pentraxin 3: A Novel Biomarker for Inflammatory Cardiovascular Disease.International journal of vascular medicine.2012
9. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-2850.
10. Obradovic R, Kesic L, Mihailovic D, Jovanovic G, Antic S, Brkic Z. Low level lasers as an adjunct in periodontal therapy in patients with Diabetes Mellitus. Diabetes Technology and Therapeutics. 2012;14(9):799-803.
11. Newman MG, Takei HH, Klokkevold PR, Carranza FA, Editor Carranza’s Clinical Periodontology.10th ed. Missouri:Saunders Elsevier; 2006. p.320.
12. Yacoubi A. microbiology of periodontitis in Diabetic patients in Oran, Algeria. Ibnosina Journal of Medicine and Biomedical Sciences 2013;5(5):280-287.
13. Gumus P, Nizam N, Nalbantsoy A, Ozcaka O, and Buduneli N. Saliva and Serum Levels of Pentraxin-3 and Interleukin-1b in Generalized Aggressive or Chronic Periodontitis. J Periodontol 2014;85:40-46.
14. Lakshmanan R, N.D. Jayakumar N D, Sankari M, Padmalatha O,and Varghese S. Estimation of Pentraxin-3 Levels in the Gingival Tissues of Chronic and Aggressive Periodontitis Participants: An In Vivo Study. J Periodontol 2014;85:290-297.
15. Mohan M, Bains VK, Gupta V, Jhingran R, Madan R and Rizvi I. Pentraxin-3 (PTX-3): A Potential Marker for Periodontal Disease Activity. Asian Journal of Oral Health & Allied Sciences 2014;4:1.
16. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-2354.
17. Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55.
18. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-167.
19. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102:636-641.
20. Yang HS, Woo JE, Lee SJ, Park SH, Woo JM. Elevated Plasma Pentraxin 3 Levels Are Associated With Development and Progression of Diabetic Retinopathy in Korean Patients With Type 2 Diabetes Mellitus Investigative Ophthalmology & Visual Science September 2014, Vol.55, 5989-5997.
21. Reading PC, Bozza S, Gilbertson B, et al. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol 2008;180:3391-3398.
22. Rashtchizadeh N, Sede SA, Ghaffari MA, Mohammadzadeh G,Majidi S. Associations of pentraxin 3 with presence and severity of coronary artery disease in type 2 diabetes patients. Turk J Biochem 2015;40(1):37–43.
23. El Meligi AA, Alaa M. Abdel Hamid AM, Aziz MA,El Haddadd HE, Ishak MF and Yousief EM. Plasma long pentraxin 3 as a marker of endothelial dysfunction in early diabetic nephropathy.2013 Egypt J Intern Med 25:117–126.
